<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>20C. Vaccinology II</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-20b-vaccination-1.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 64.10%;"></div> <!-- (25/39)*100 -->
                        </div>
                       <span class="progress-text">Lecture 25 of 39</span> 
                    </div>
                    <a href="immunology-21a-tumor-immunology.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Vaccinology II</h1>
                <p>MBChB II 4/7/11</p>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: section-definitions-principles -->
                <section id="section-definitions-principles" class="content-section" aria-labelledby="section-heading-definitions-principles">
                    <h2 id="section-heading-definitions-principles" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Definitions and Immunological principles</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Manipulation of the immune system to the benefit of the patient</li>
                            <li>The adaptive immune response is manipulated in an antigen-specific manner to stimulate lymphocyte-mediated protective immunity</li>
                            <li><strong>Passive immunization:</strong> administration of preformed antibody ("antiserum") derived form human or animal donors to the recipient
                                <ul>
                                    <li>The effect is immediate but shortlived as the transferred immunoglobulin is metabolized.</li>
                                    <li>Immunological memory does not develop</li>
                                </ul>
                            </li>
                            <li><strong>Vaccination (active immunization):</strong> attenuated organisms, killed organisms or pathogen subunits are administered to an individual
                                <ul>
                                    <li>The immune response develops slowly but immunological memory is evoked</li>
                                    <li>Re-exposure of the subject to the pathogenic organism produces a rapid, effective secondary response, which prevents symptomatic infection</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-definitions-principles -->

                <!-- START: section-type-of-vaccines -->
                <section id="section-type-of-vaccines" class="content-section" aria-labelledby="section-heading-type-of-vaccines">
                    <h2 id="section-heading-type-of-vaccines" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Type of vaccines</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li><strong>Killed vaccines</strong> - preparations of normal infectious, pathogenic virus or bacteria that has been rendered non-pathogenic, usually by chemical treatment such as with formalin - cross-links viral proteins</li>
                            <li><strong>Attenuated vaccines</strong> - live virus or bacteria particles that grow in the vaccine recipient but do not cause disease as they have been altered (mutated) to a nonpathogenic form</li>
                            <li><strong>Subunit vaccines</strong> - purified components of the virus, such as a surface antigen</li>
                            <li><strong>Toxoid</strong> - inactivated toxic compound</li>
                            <li><strong>Conjugate</strong> - polysaccharide capsule linked to a protein to increase the antigenicity</li>
                            <li><strong>Recombinant vector</strong> - physiology of one micro-organism combined to DNA of another</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-type-of-vaccines -->

                <!-- START: section-aims-disease-control -->
                <section id="section-aims-disease-control" class="content-section" aria-labelledby="section-heading-aims-disease-control">
                    <h2 id="section-heading-aims-disease-control" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Aims of disease control to be achieved by immunization</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li><strong>Containment</strong> - accepts that disease will remain endemic but seeks to reduce morbidity to an acceptable level.</li>
                            <li><strong>Elimination</strong> - no endemic transmission in a population. Sporadic cases will occur because of imported cases, but transmission in immunized population fails to reestablish endemic transmission.</li>
                            <li><strong>Eradication</strong> - global destruction of pathogen allowing for cessation of all control measures achieving huge cost benefits for future generations.
                                <ul>
                                    <li>Requires the absence of an animal host & a vaccine effective in preventing disease transmission.</li>
                                    <li>Smallpox only human disease eradicated thus far.</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-aims-disease-control -->

                <!-- START: section-passive-immunization-uses -->
                <section id="section-passive-immunization-uses" class="content-section" aria-labelledby="section-heading-passive-immunization-uses">
                    <h2 id="section-heading-passive-immunization-uses" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Passive immunization - clinical uses</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Treatment of serious infections</li>
                            <li>Secondary prevention post-exposure in individuals at high risk of mortality - botulism, rabies, tetanus, hepatitis B</li>
                            <li>Neutralization of toxins (e.g. postsnake bite) and digitalis overdose (neutralizing antibody to inactivate the drug)</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-passive-immunization-uses -->

                <!-- START: section-active-immunization -->
                <section id="section-active-immunization" class="content-section" aria-labelledby="section-heading-active-immunization">
                    <h2 id="section-heading-active-immunization" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Active immunization (vaccination)</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Produces an immune response capable of providing effective protective immunity in the absence of symptomatic infection</li>
                            <li>In any population, some individuals will have contra-indications to particular vaccines or will fail to respond</li>
                            <li>However, if 95% of the population are vaccinated, those non-vaccinated subjects are unlikely to come in contact with an infected subject (herd immunity)</li>
                            <li><strong>Live attenuated vaccines</strong> - provide strong immunization of the appropriate type & site for natural infection
                                <ul><li>Risk of reversion to pathogenic strains causing disease. Pose a particular risk especially immunocompromised subjects</li></ul>
                            </li>
                            <li><strong>Killed vaccines</strong> - do not pose a risk of infection.
                                <ul><li>Elicit weaker responses than live attenuated vaccines. Booster doses are usually required</li></ul>
                            </li>
                             <li><strong>Subunit vaccines</strong> - contain proteins, carbohydrates, or inactivated toxins from organisms.
                                <ul>
                                    <li>Less immunogenic than intact organisms, and may require adjuvants to elicit effective immune responses</li>
                                    <li>Schedules usually involve multiple doses</li>
                                    <li>Side effects are less prominent than with whole organisms</li>
                                    <li>No risk of vaccine-associated infection</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-active-immunization -->

                <!-- START: section-vaccination-clinical-uses-schedule -->
                <section id="section-vaccination-clinical-uses-schedule" class="content-section" aria-labelledby="section-heading-vaccination-clinical-uses-schedule">
                    <h2 id="section-heading-vaccination-clinical-uses-schedule" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Vaccination - clinical uses</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Some vaccines are offered to everyone, while others are reserved for people at particular risk because of an underlying medical condition, occupational risk or travel</li>
                            <li>Schedules of routine vaccination vary in different parts of the world</li>
                        </ul>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Common Vaccines, Types, and Indications/Schedule</caption>
                                <thead>
                                    <tr>
                                        <th>VACCINE</th>
                                        <th>TYPE</th>
                                        <th>INDICATIONS, SCHEDULE</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>BCG</td>
                                        <td>Live attenuated</td>
                                        <td>Birth</td>
                                    </tr>
                                    <tr>
                                        <td>Tetanus</td>
                                        <td>Toxoid</td>
                                        <td>Childhood, 3 doses</td>
                                    </tr>
                                    <tr>
                                        <td>Diphtheria</td>
                                        <td>Toxoid</td>
                                        <td>"</td>
                                    </tr>
                                    <tr>
                                        <td>Pertussis</td>
                                        <td>Subunit or cellular</td>
                                        <td>"</td>
                                    </tr>
                                    <tr>
                                        <td>HiB</td>
                                        <td>Conjugated polysaccharide</td>
                                        <td>"</td>
                                    </tr>
                                    <tr>
                                        <td>Hepatitis B</td>
                                        <td>Subunit</td>
                                        <td>Childhood; occupational risk, 3 doses</td>
                                    </tr>
                                    <tr>
                                        <td>Measles</td>
                                        <td>Live attenuated</td>
                                        <td>Single dose at 9 months</td>
                                    </tr>
                                    <tr>
                                        <td>Polio</td>
                                        <td>Live attenuated or killed</td>
                                        <td>Childhood; 3 doses</td>
                                    </tr>
                                    <tr>
                                        <td>Influenza</td>
                                        <td>Subunit; new preparation on annual basis</td>
                                        <td>Medical risk - chest dz, elderly, diabetes, immunocompromised)<br>Environmental risk - nursing homes<br>Occupational risk - healthcare workers</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: section-vaccination-clinical-uses-schedule -->

                <!-- START: section-contraindications-vaccination -->
                <section id="section-contraindications-vaccination" class="content-section" aria-labelledby="section-heading-contraindications-vaccination">
                    <h2 id="section-heading-contraindications-vaccination" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Contra-indications to vaccination</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Moderate or severe illness, with or without fever</li>
                            <li>Anaphylactic reaction to vaccine or its constitute</li>
                            <li>Live attenuated vaccines:
                                <ul>
                                    <li>Pregnant women</li>
                                    <li>Immunocompromised children</li>
                                    <li>Within 3 months of intravenous immunoglobulin</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-contraindications-vaccination -->

                <!-- START: section-ideal-vaccine-properties -->
                <section id="section-ideal-vaccine-properties" class="content-section" aria-labelledby="section-heading-ideal-vaccine-properties">
                    <h2 id="section-heading-ideal-vaccine-properties" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Properties of an ideal vaccine WHO</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Safe</li>
                            <li>Affordable worldwide</li>
                            <li>Heat stable</li>
                            <li>Effective after a single dose</li>
                            <li>Applicable to a number of diseases</li>
                            <li>Administered by a mucosal route</li>
                            <li>Suitable for administration early in life</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-ideal-vaccine-properties -->

                <!-- START: section-modern-approaches-vaccine-dev -->
                <section id="section-modern-approaches-vaccine-dev" class="content-section" aria-labelledby="section-heading-modern-approaches-vaccine-dev">
                    <h2 id="section-heading-modern-approaches-vaccine-dev" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Modern approaches to vaccine development</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Development of more effective & safer vaccines, as well as vaccines for other diseases is a major area of research</li>
                            <li>Molecular techniques have facilitated the production of large quantities of proteins for use as subunit vaccines safely & relatively cheaply</li>
                            <li>Vaccination has been particularly successful in diseases where natural infection leads to sterilizing immunity and long-term immunity. Many other diseases remain major public health problems</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-modern-approaches-vaccine-dev -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-20b-vaccination-1.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 64.10%;"></div> 
                        </div>
                       <span class="progress-text">Lecture 25 of 39</span> 
                    </div>
                    <a href="immunology-21a-tumor-immunology.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> 
</body>
</html>